France: Elyan to acquire majority stake in Oncodesign’s CRO activities following company split

Elyan Partners, a partner member of Edmond de Rothschild Private Equity, is to acquire a majority stake in Oncodesign’s service (ODS) business for around €100m (US$102.5m) following Oncodesign’s decision to split into two activities: Service and Biotech. Elyan will acquire a controlling block of 52.17% of the capital. Philippe Genne, chairman, CEO and founder of…

You must be a HMI Subscriber to view this content.

Subscribe Now »